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Abstract 
Background: Tumour cells release membrane micro(nano)fragments called tumour‑derived microvesicles (TMV) 
that are believed to play an important role in cancer progression. TMV suppress/modify antitumour response of the 
host, but there is also some evidence for their direct interaction with cancer cells. In cancer patients TMV are present 
in body fluid and tumour microenvironment. The present study aimed at characterization of whole types/subpopula‑
tions, but not only exosomes, of TMV from newly established gastric cancer cell line (called GC1415) and to define 
their interactions with autologous cells.
Methods: TMV were isolated from cell cultures supernatants by centrifugation at 50,000×g and their phenotype was 
determined by flow cytometry. The size of TMV was analysed by dynamic light scattering and nanoparticle tracking 
analysis, while morphology by transmission electron microscopy and atomic force microscopy. Interactions of TMV 
with cancer cells were visualized using fluorescence‑activated cell sorter, confocal and atomic force microscopy, bio‑
logical effects by xenografts in NOD SCID mice.
Results: Isolated TMV showed expression of CD44H, CD44v6 (hyaluronian receptors), CCR6 (chemokine receptor) and 
HER‑2/neu molecules, exhibited different shapes and sizes (range 60–900 nm, highest frequency of particles with size 
range of 80–120 nm). TMV attached to autologous cancer cells within 2 h and then were internalized by them at 24 h. 
CD44H, CD44v6 and CCR6 molecules may play a role in attachment of TMV to cancer cells, while HER‑2 associated 
with CD24 be involved in promoting cancer cells growth. Pre‑exposure of cancer cells to TMV resulted in enhance‑
ment of tumour growth and cancer cell‑induced angiogenesis in NOD SCID mice model.
Conclusions: TMV interact directly with cancer cells serving as macro‑messengers and molecular cargo transfer 
between gastric cancer cells resulting in enhancement of tumour growth. TMV should be considered in future as 
target of anticancer therapy.
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Background
Interactions/communications between tumour cells 
themselves and tumour cells with the microenvironment 
are responsible for cancer development and progression 
[1], but the pathomechanism(s) of cancer progression are 
far from clear. Tumour microenvironment plays a major 
role in this process, as both infiltrating and tumour cells 
produce a range of soluble mediators with protumour 
activity (e.g. interleukin-6, transforming growth fac-
tor β, epidermal growth factor and its receptor, vascular 
endothelial growth factor, etc.). However, immunother-
apy approaches employing various monoclonal antibod-
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receptors, are only partially effective [2]. Therefore, there 
must be another mechanism(s) responsible for cancer 
progression.
Recently, there has been an increasing interest in 
studying tumour cells surface micro(nano)fragments 
also called micro(nano)vesicles (MV). MV are defined 
as spherical proteolipids with sizes ranging from 30 nm 
to 1 μm [3]. MV circulate in blood of healthy individuals 
and their elevated numbers are found in patients with 
various diseases, including cancer [4, 5]. They are shed 
by many cell types, in particular rapidly proliferating. 
Tumour cells, in particular more malignant, release MV 
called tumour-derived MV (TMV). They are present in 
body fluids and tumour microenvironment [1]. In some 
types of cancer (ovarian, breast, gastric) elevated num-
bers of MV, not necessarily of tumour origin, are asso-
ciated with poor prognosis [4–6]. MV carry various 
surface determinants and mRNA/miRNA and transfer 
some of them to other cells (e.g. blood cells), hence are 
regarded as important messengers in cell to cell com-
munication [7–9]. TMV inhibit antitumour response 
of the host [10] and may play a pivotal role in cancer 
progression [1, 11]. There is some evidence that tumour 
cell-derived exosomes (particles with sizes <100  nm), 
that TMV contain, interact with autologous tumour 
cells. Firstly, TMV entry to recipient cells, including 
prostate, lung and breast cancer [12]. Secondly, gastric 
cancer exosomes promote tumour cell proliferation, 
at least in part, by activation of PI3K/Akt and MAPK/
EPK pathways [13]. Thirdly, TMV contain selectively 
secreted components which are required for metastasis 
formation, e.g. in breast and non-small lung cancer [14, 
15].
We have previously described the characteristics of 
circulating MV in blood of gastric cancer patients, and 
concluded that at least some of them may be of tumour 
origin [5]. As little is known about TMV from gastric 
cancer cells, we have established the novel gastric can-
cer cell line (called GC1415) and characterized immu-
nophenotype, including expression of tumour markers 
of cells and TMV derived from them. The aim of these 
studies was to characterize all particles shed/released by 
tumour cells, but not only isolated exosomes, i.e. par-
ticles with sizes less than 100 nm, as the latter may not 
be representative for whole types/subpopulations of 
TMV. Their size, physical properties and morphology 
was determined. Isolated TMV were used to define their 
interactions with cancer cells they derived from. The 
present study shows that TMV attached to the cell sur-
face and then were internalized as visualized indepen-
dently by three different methodologies. Furthermore, 




Tumour cell line GC1415 was recently established in our 
laboratory from carcinomatous ascites of a patient with 
advanced gastric (adenocarcinoma) cancer. These stud-
ies were approved by the Jagiellonian University Medical 
College Ethical Committee (KBET/491/B/2003). The cells 
were cultured in DMEM with high glucose content (PAA 
Laboratories GmbH, Pasching, Austria) supplemented 
with 5  % foetal bovine serum (FBS, Biowest, Nuaille, 
France) at 37  °C, in 5  % CO2 atmosphere and regularly 
tested for Mycoplasma sp. contamination by PCR-ELISA 
kit (Roche, Mannheim, Germany) and for endotoxin con-
tamination by the Limulus test (Charles River Laborato-
ries, Wilmington, MA) according to the manufacturers’ 
instruction.
TMV isolation
GC1415 cells were cultured by bi-weekly passages in 
DMEM with 5 % FBS previously centrifuged at 50,000×g 
for 1  h to remove bovine MV. Supernatants from the 
cultures at confluency were collected and spun down 
at 3000×g for 10  min to remove cellular debris. Then, 
supernatants were centrifuged using RC28S ultracentri-
fuge (Sorvall, Newton, CT) at 50,000×g for 1 h at 4  °C. 
Pellets were washed several times in serum-free DMEM 
to remove FBS, and finally resuspended in it. Quantifica-
tion of TMV protein concentration was evaluated by the 
Bradford’s method using Quick Start Bradford Dye Rea-
gent (BioRad, Hercules, CA). The number of TMV was 
determined by flow cytometry (FACS Canto, BD Bio-
sciences Immunocytometry Systems, San Jose, CA) and 
nanoparticle tracking analysis (NTA) using NanoSight 
system, i.e. LM10HS microscope equipped with the 
LM14 488 nm laser module (Malvern Instruments Ltd., 
Malvern, UK). TMV were also tested for Mycoplasma sp. 
and endotoxin contamination and stored at −20  °C for 
further usage.
Flow cytometry
The following murine IgG1 monoclonal antibod-
ies (mAbs) were used: phycoerythrin (PE)-conjugated 
anti-CD44H and fluorescein (FITC)-conjugated anti-
CD44v6 (eBioscience GmbH, Vienna, Austria), PE-
conjugated anti-CCR6, anti-EGFR and allophycocyanin 
(APC)-conjugated anti-HER-2/neu (BD Biosciences, 
San Diego, CA), PE-conjugated anti-Mucin1 and anti-
EMMPRIN (Santa Cruz Biotechnologies, Santa Cruz, 
CA), FITC-conjugated anti-EpCAM (DAKO, Glostrup, 
Denmark). Isotype controls included appropriate FITC-, 
PE- or APC-labelled mouse immunoglobulins. Cancer 
cells (1 × 105 per sample) or TMV (1 μg per sample) were 
incubated with appropriate saturating concentrations of 
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mAbs for 20 min at 4  °C, washed (except TMV), resus-
pended in phosphate buffered saline (PBS) and analysed 
by FACS.
Determination of HER‑2/neu and MAGE‑1, ‑2 mRNA 
expression
Total RNA was isolated from the GC1415 tumour cells 
(1 ×  106) and their TMV using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. The cDNA synthesis and nested, 
“real-time” PCR for MAGE-1, -2 and β-actin was per-
formed as previously described [16]. For the detection 
of HER-2/neu mRNA “real time” PCR was performed 
using the following primer pair: for HER-2/neu: sense-
5′-CCTCTGACGTCCATCATCTC-3′ and antisense-
5′-ATCTTCTCGTGCCGTCGCTT-3′. The cycle 
profile for HER-2/neu PCR run was as follows: initial 
denaturation at 95 °C for 10 min, then denaturation at 
95  °C for 0 s, annealing at 60  °C for 35 s, and elonga-
tion at 72  °C for 35  s for 35 cycles, followed by final 
extension at 72 °C for 2 min. All the results were nor-
malized with β-actin data and were presented as ΔCT. 
To verify the amplified product, melting curve analysis 
using the 2.3 LightCycler software was performed for 
each sample.
Determination of TMV size distribution
Size distribution using the dynamic light scattering (DLS) 
was determined as previously described [5]. Briefly, sam-
ples either diluted or not (depending on signal intensity) 
in 0.15  M NaCl were measured in Zetasizer Nano ZS 
apparatus (Malvern Instruments) equipped with laser of 
λ = 633 nm. Size distribution was obtained from meas-
ured diffusion coefficients recalculated to the size by 
assuming spherical shape of particles. The obtained val-
ues represent the diameter of spherical particles which 
move in viscous media with the same velocity as TMV. 
The size and distribution of TMV was also determined 
by NTA. For this purpose TMV samples were diluted 200 
times in prefiltered (0.2 μm), sterile PBS to the total vol-
ume of 1 ml, then aspirated into an insulin-type syringe 
and loaded into the sample chamber. The TMV size and 
distribution measurements were collected in triplicates 
of 1  min film intervals recorded by the sCMOS camera 
and calculated using the NanoSight NTA 2.3 analytical 
software.
Zeta potential determination
Particle electrophoretic mobility was measured with 
Zetasizer Nano ZS apparatus (Malvern Instruments) 
in samples 10 times diluted with distilled water (to final 
ionic strength equal to 0.015 M) and recalculated to Zeta 
potential using Smoluchowsky’s equation, as previously 
described [6].
Transmission electron microscopy (TEM)
Purified TMV were mixed with 2 % of uranyl acetate and 
applied to carbon coated copper grid. The microphoto-
graphs were taken with Philips EM 300 electron micro-
scope (Philips, Eindhoven, The Netherlands) operating at 
80 kV.
Atomic force microscopy (AFM)
AFM was used to determine morphology of TMV. Sam-
ples for AFM were prepared from TMV suspensions by 
adsorbing onto highly ordered pyrolytic graphite (ZYH—
mosaic spread 3.5–5.0) supports (NT-MDT Co., Zele-
nograd, Russia). The measurements were performed 
using Ntegra Vita microscope (NT-MDT Co.). The AFM 
images were recorded in semicontact mode. Experi-
ments were performed using the commercial silicon tip 
with polysilicon cantilever (NT-MDT Co.) and resonance 
frequency within the range of 140–240  kHz and spring 
constants k = 3.4 N/m or k = 5.8 N/m. AFM imaging of 
cancer cells were acquired in phase contact mode, which 
reflects both morphology and mechanical properties of 
the sample. Image Analysis 2.2.0 software from NT-MDT 
Co. was used for AFM image processing.
Binding and engulfment of TMV
FACS analysis
To test the ability of TMV to bind to tumour cells, TMV 
were stained with red PKH26 fluorescent dye (Sigma-
Aldrich, St. Louis, MO) for 5  min, according to the 
manufacturer’s instruction and then incubated with 
GC1415 cells (app. 10 TMV per cell) for 2 and 24 h. To 
discriminate between the cells which already engulfed 
TMV (intracellular localization) from those with TMV 
only attached to their surface (extracellular) quenching 
assay with crystal violet (Sigma-Aldrich, 1  mg/ml final 
concentration), was applied according to the manufac-
turer’s instructions [17]. The samples were then analysed 
by FACS, where gate P1 was set according to autofluores-
cence of GC1415 cells incubated in the medium without 
TMV (negative control).
AFM analysis
For AFM analysis, tumour cells (2 ×  104 per well) were 
cultured in DMEM with 1  % FBS for 48  h on Lab-Tek 
Chamber Slide (Nalgene Nunc International, Naperville, 
IL). Then, cells were incubated with TMV (at the ratio 
1:10) for the next 24  h, washed and assessed by AFM, 
as described above, except that the cells were analysed 
directly on the slide and pictures were presented in phase 
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contrast mode, which reflects both morphology and 
mechanical properties of the sample.
Confocal microscopy analysis
GC1415 cells (1 × 106 per ml) were cultured in DMEM 
with 10  % FBS on Super Frost Plus microscopy slides 
(Menzel-Glaser, Braunschweig, Germany) for 48  h. 
TMV were incubated for 5  min with red PKH26 dye 
(Sigma-Aldrich) according to manufacturer’s instruc-
tion. Then, TMV were washed with 1  % bovine serum 
albumin and several times in serum-free DMEM 
medium. PKH26-labelled TMV resuspended in the 
medium were added to GC1415 cells and incubated for 
2 and 24 h. As control the cells were processed identi-
cally without TMV. After incubation, cells with intact 
plasma membrane were labelled with fluorescein, fol-
lowing hydrolysis of fluorescein diacetate (Sigma-
Aldrich), as described by Rotman and Papermaster [18]. 
Life cell imaging was used to visualize extra- and intra-
cellular localization of TMV (red fluorescence, GC1415 
cells-green fluorescence). Images were acquired by 
Leica TCS SP5 laser scanning confocal microscope 
(Leica Microsystems CMS GmbH, Mannheim, Ger-
many) equipped with 63x, NA1.4 planapochromatic oil 
immersion objective. During imaging cells were main-
tained at 37 °C in DMEM/F12 medium without phenol 
red (Sigma-Aldrich), supplemented with 2  % FBS. The 
confocal pinhole size was set at 1 Airy unit. PKH26 flu-
orescence was excited with 543 nm line of He/Ne diode 
laser and emission was recorded in the range of 570–
640  nm. For excitation of fluorescein 488  nm line of 
argon ion laser was used and the emission was recorded 
in the range of 500–540 nm. Image processing and anal-
yses were performed by LAS AF (Leica Microsystems) 
software.
Xenografts of GC1415 cells in NOD SCID mice
The GC1415 cells (1  ×  106 per mouse) suspended in 
200  μl of PBS were injected subcutaneously into dor-
sal region of 8-weeks old NOD SCID mice purchased 
from Charles River Laboratories (Sulzfeld, Germany). 
Handling of mice and all procedures were performed 
under laminar flow conditions. In some experiments 
tumour cells were preincubated with autologous TMV 
(9 ×  106) for 2 or 24  h, washed and then injected. The 
cells preincubated in the culture medium alone were 
used as control. Mice (5 per group) were checked every 
7  days and the tumour diameter was measured with a 
caliper and its volume (v) was calculated according to 
the formula: v =  ab2/2 [19]. The tissues were examined 
macroscopically for metastases in the spleen, liver, lung, 
lymph nodes, kidney and then processed for histological 
examination.
Angiogenesis assay
Tumour cells, with or without TMV, were prepared as 
above, washed and resuspended in 100 μl of PBS. Then, 
cells were mixed with 400 μl of Matrigel Matrix (BD Bio-
sciences) and injected subcutaneously into the abdominal 
middle line of NOD SCID mice. After 6 days mice were 
euthanized, Matrigel Matrix pellets were cut out and then 
400  μl of Cell Recovery Solution (BD Biosciences) was 
added and left at 4  °C for 7 days. Then, Matrigel Matrix 
implants were suspended in Drabkin’s solution (Sigma-
Aldrich) for 30  min, after that spun down and the con-
tent of haemoglobin was determined by measuring the 
absorbance (O.D.) at 540 nm in U-1800 spectrophotom-
eter (Hitachi, Tokyo, Japan) [20]. Independently Matrigel 
plugs after cutting out were photographed and then fixed 
in formalin, paraffin embedded, serial 3 μm sections were 
cut and stained with hematoxylin and eosin.
Statistical analysis
The nonparametric Mann–Whitney two-sided test was 
performed using GraphPad InStat version 2.0 software. P 
values <0.05 were considered significant.
Results
Immunophenotype of tumour cells and TMV
The CD44H (hyaluronian receptors), CD44v6, CCR6 
(chemokine receptors) and EGFR (epithelial growth fac-
tor receptor) are involved in interactions of tumour 
cells with monocytes [21, 22]. The question was raised 
whether these receptors, by analogy, play a similar role 
in TMV-cancer cells interactions. Therefore, appro-
priate mAbs against these determinants were used to 
detect their expression on GC1415 cells and TMV. The 
presence of some tumour markers was also determined. 
The comparison of expression of tested determinants 
showed remarkable differences between tumour cells and 
their TMV (Fig.  1). The majority of cells were positive 
for CD44H and EGFR and about 50 % for CD44v6. The 
expression of EMMPRIN was observed on app. 20–60 % 
cells, CCR6 on 10–14  %, while few cells were EpCAM, 
EGFR and Mucin1 positive. Among analysed tumour 
markers, HER-2/neu was detected on all cells, but CEA 
and TAG-72 presence was not observed. The expression 
level of CD44H, EMMPRIN, HER-2/neu, EpCAM, EGFR 
and Mucin1 on TMV was significantly lower or absent, 
except CD44v6 and CCR6 which was comparable on cells 
and their TMV. The staining for MAGE-1, -2 was not 
performed due to the lack of suitable mAbs.
The MAGE‑1, ‑2 and HER‑2/neu mRNA expression
The expression of mRNA for MAGE-1, 2 and HER-2/neu 
was detected in both the cells and TMV, however, it was 
lower in TMV compared to the GC1415 tumour cells as 
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viewed by the threshold cycle value (ΔCT). For the mRNA 
expression of MAGE-1, -2 and HER-2/neu in TMV the 
ΔCT values were as follows: 6.163 ± 1.439, 7.897 ± 1.385, 
6.890 ± 1.473, where as in the GC1415 tumour cells they 
were 4.990 ± 3.167, 2.673 ± 4.031, 5.21 ± 2.598, respec-
tively. Melting curve analysis confirmed the specificity of 
the PCR products.
The physical characteristics of TMV
The effective size range of TMV as determined by DLS 
analysis was between 60–900 nm (Fig. 2a) and the most 
frequent events were around 80 nm (Fig. 2b). By NTA the 
reciprocal values were 70–520  nm and around 120  nm 
(Fig.  2c), respectively. Electrokinetic (Zeta) potential of 
TMV, which define the effective charge of objects, was 
Fig. 1 Expression of some CD determinants and tumour markers on GC1415 cells and their TMV. Immunophenotype was determined by FACS 
analysis
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−23.5 ± 1.80 mV. TEM and AFM were used to determine 
the morphology and size of TMV. TMV did not exhibit 
any characteristic features and were of different sizes and 
shapes, mostly spheroid (Fig. 2d, e). Base cross-sections 






































Fig. 2 The physical characteristics of TMV determined by DLS, NTA, TEM and AFM. a Size range and b size frequency of TMV by DLS. c Representa‑
tive size frequency by NTA. d TEM, e 2D AFM and f 3D images (5 × 5 µm area) of TMV deposited onto pyrolytic graphite. Sizing of objects present 
along the line marked in part (e): x‑axis—size, y‑axis—height
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Binding and engulfment of TMV by autologous cancer cells
To test the ability of TMV to interact with autologous 
(parental) cancer cells, GC1415 cells were incubated with 
PKH26-labelled TMV. FACS analysis indicated that after 
2 h of culture about 70 % of GC1415 cells were fluorescent, 
which increased to 99 % after 24 h (Fig. 3b, d). To discrimi-
nate, whether TMV only adhered to the cell surface or 
were engulfed by the cells, crystal violet was added. After 
quenching, the percentage of positive cells decreased to 
16.8 and 37.7 % at 2 and 24 h, respectively (Fig. 3f, h), thus 
indicating intracellular localization of TMV.
To confirm localization of TMV in GC1415 cells con-
focal microscopy was applied. When GC1415 cells were 
incubated with PKH26-labelled TMV for 2  h the red 
fluorescence of the vesicles was associated with plasma 
membranes (Fig.  4a), however following a 24  h incuba-
tion the majority of TMVs were detected inside the cells 
(Fig. 4b). TMV localized intracellularly were of different 
size. AFM analysis of control and TMV-treated GC1415 
cells showed at 24 h, but not 2 h, significant differences 
in their surface outlook. The cells not exposed to TMV 
(Fig. 5a) showed smooth surface and sharp contour. After 
incubation with TMV (Fig. 5b) the cell surface was rough, 
uneven with visible protuberations. The cells edges were 
thicker and diffused of torus shape.
Tumour growth and angiogenesis
Inoculation of NOD SCID mice with GC1415 cells led 
to the formation of tumours in all animals. Palpable 
tumours appeared around 3  weeks with a rapid growth 
thereafter. Observation period was 8  weeks. No metas-
tases in the lung, liver, spleen, kidney, lymph nodes were 
detected either macro- or microscopically. Engraftment 
of GC1415 cells exposed to TMV in  vitro for 2 or 24  h 
led in the latter case in a slight, but significant, increase 
of tumour volume as compared to untreated cells 
(Fig.  6a, b). Metastases were also not detected. Angio-
genesis measured quantitatively by haemoglobin content 
showed significant increase when GC1415 cells were 
pre-exposed to TMV for 24 h, but not 2 h (Fig. 6c). Visu-
alization of excised Matrigel plugs also showed the same 
(Fig. 6d). Histological analysis of the same plugs revealed 
that when tumour cells were used alone, examined 
areas show either no or few vessels (Fig. 6e, i, ii). When 
Matrigel Matrix containing GC1415cells and TMV were 
implanted, both vessels and cells were more numerous, 
less when tumour cells were pre-exposed to TMV for 2 h 
(Fig. 6e, ii) and significantly more pronounced in case of 
cells preincubated with TMV for 24 h (Fig. 6e, iv). It was 
concluded, that TMV may enhanced tumour growth and 
angiogenesis.
Fig. 3 Binding to and engulfment of TMV by GC1415 cells. FACS analysis of GC1415 cells after incubation in the medium (a, c, e, g) or with TMV. 
GC1415 cells were pre‑treated with PKH26‑labelled TMV for 2 h (b, f) or 24 h (d, h). The same samples were treated with crystal violet solution (e, f, 
g, h) as described in “Methods”. Gate P1 was set according to autofluorescence of GC1415 cells incubated in the medium without TMV. The percent‑
age of TMV containing cells is shown
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Discussion
The role of MV and TMV in cancer is unclear. They are 
present in the circulation [5, 23] and probably involved 
in cancer progression, as shown by association of MV 
(not necessarily of tumour origin) level with poor sur-
vival of cancer patients [4]. They may act by inhibiting/
hiding antitumour immune response [10] or like tumour-
derived exosomes by interacting directly with tumour 
cells [7, 13, 24]. Current data clearly indicate that tumour 
microenvironment plays a major role in the inhibition 
or enhancement of cancer progression. TMV that are 
present at the tumour site [1] may either induce cellular 
antitumour response [25] and release antitumour solu-
ble factors [26] or, more likely, exhibit a tumour support-
ing role [27]. The latter may be due to the induction of 
growth factors production by tumour cells themselves or 
infiltrating cells, including macrophages, and/or by pro-
moting the differentiation of myeloid cells into immuno-
suppressive cell subsets [28].
We have previously reported increased levels of cir-
culating MV and their characteristics in blood of gastric 
cancer patients [5]. Since it is difficult to determine pre-
cisely which of these MV are of tumour origin, this gas-
tric cancer cell line was established and its TMV were 
isolated and characterized in order to compare them 
with circulating MV. The immunophenotype analysis 
confirmed the other data showing that the expression of 
some determinants on TMV is much lower than on cells 
[26, 29, 30]. Only CCR6 and CD44v6 expression was 
comparable on both, cells and their TMV. CCR6 recep-
tor was detected on some cells of pancreatic, colorectal 
and lung cancer cell lines and their TMV [26], circulat-
ing tumour cells [31] and plasma MV of gastric cancer 
patients [5]. This may suggest its involvement in cancer 
progression [32]. CCR6 is being identified as a potential 
new prognostic marker in some types of tumours and 
the axis of CCL20/CCR6/IL-17 may be a new therapeu-
tic target in cancer [33]. The high expression of CCL20 
may contribute to the selective recruitment of CCR6 
positive cancer cells and metastases formation [32]. We 
have previously demonstrated that CCR6 transferred via 
TMV to monocytes is biologically active, as monocytes 
acquired chemotactic activity to CCL20 [26]. Based 
on that, it is reasonable to assume that CCR6 transfer 
between cancer cells, as exemplified by the attachment 
of PKH26-labelled TMV, may be a likely mechanism 
responsible for the enhancement of tumour growth. The 
presence of CD44H, CD44v6 (hyaluronian receptors) 
on TMV may also facilitate their interaction with can-
cer cells, known to abundantly express hyaluronian [34]. 
This may be analogous to its role in interaction of cancer 
cells with monocytes, resulting in the induction of reac-
tive oxygen intermediates production [22]. Also, high 
expression of CD44v6 determinants on TMV may sug-
gest their role in tumour progression, as soluble matrix 
delivered by CD44v6 is required for premetastatic niche 
formation [35]. Taken together, it is suggested that 
CD44H, CD44v6 and CCR6 may be involved in attach-
ment rather than internalization of TMV. By analogy to 
exosomes, internalization of TMV may occur by various 
pathways of uptake [7], because the cleavage of exosome 
surface proteins reduced their association with target 
cells [12].
Fig. 4 Localization of PKH26‑labelled TMV (red fluorescence) in 
GC1415 cells (green fluorescence). Maximum intensity projection 
of three middle confocal planes are displayed. Confocal micros‑
copy images of GC1415 cells exposed to TMV for 2 h (a) or 24 h (b) 
demonstrating plasma membrane attached (a) and internalised (b) 
TMV; TMV free control for PKH26 labelling for 2 h (c) and 24 h (d) are 
shown. A horizontal and vertical sections of the 3D images are also 
presented. Arrows indicates positions of each section
Fig. 5 AFM images (phase contrast mode) of GC1415 cells surface 
without contact (a) or exposed (b) to TMV for 24 h. Scan area 
20 × 20 µm. Phase contrast presentation refers to the phase shift of 
signal due to the mechanical properties of the sample
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Fig. 6 TMV effect on the GC1415 tumour growth and angiogenesis in NOD SCID mice. Before engrafting into NOD SCID mice GC1415 cells were 
or not exposed to TMV in vitro. Kinetic curve of tumour growth of cells exposed (or not) to TMV for 2 h (a) and 24 h (b). Angiogenesis as assessed 
quantitatively by haemoglobin content (c). Bars represent the mean ± SD from three experiments. Angiogenesis visualised as Matrigel plugs 
photos (d) and histological analysis (e). i‑cells alone, ii‑cells + TMV after 2 h incubation, iii‑ cells alone and iv‑ cells + TMV after 24 h pre‑exposure. 
*Significantly different (p < 0.01) in comparison to control
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The expression of tumour markers (Mucin1, EMM-
PRIN, EpCAM, EGFR) on TMV was low or absent, 
despite their presence on cells. Although almost all 
cells were HER-2/neu positive, small proportion of 
TMV expressed this marker. The presence of mRNA 
for HER-2/neu, MAGE-1, -2 in TMV was also detected, 
although it was lower than in the tumour cells. These 
mRNAs were also found in circulating MV in plasma of 
gastric cancer patients [5]. The mRNA for interleukin-8 
[8], EGFRvIII [36] and for housekeeping genes such as 
ACTB, GAPDH [24] were detected in the cargo of TMV 
and tumour-derived exosomes and shown to be trans-
ferred to monocytes [8], brain microvascular endothelial 
cells [36] and tumour cells [24], respectively. Moreover, 
TMV containing EGFRvIII released by more aggressive 
glioma cells were found to be responsible for the transfer 
of this receptor to indolent cells, which in turn caused the 
activation of transforming signaling pathways (MAPK 
and AKT) and changes in other gene expression (VEGF, 
Bcl-xL, p27) resulting in morphological transformation 
[37]. Altogether, it is reasonable to assume that the trans-
fer of HER-2/neu molecule, its mRNA as cargo carried 
by engulfed TMV, and in result HER-2/neu expression by 
cancer cells may be associated with tumour progression, 
as observed in breast cancer [38].
The size range of TMV between app. 60–900 nm and 
the most frequent particle sizes at 80 nm determined by 
DLS were comparable to 70–520 and 120  nm by NTA, 
respectively. Similar size ranges were reported for circu-
lating MV in patients with ovarian and gastric cancers 
[5, 39]. TMV size determined by AFM was also similar. 
The smaller values of the height in AFM can be explained 
as a result of probing soft material by relatively hard 
cantilevers. Thus, the measured altitudes provide only 
a comparison of the relative size of objects. Morpho-
logical characteristics of TMV by TEM and AFM indi-
cated no major differences in comparison to circulating 
patients’ MV [5]. Such analysis revealed that both MV 
and TMV particles are mostly spheroid in shape and of 
different sizes. TMV possessed high (negative) electro-
kinetic potential. This is in keeping with higher absolute 
zeta potential values of MV isolated from plasma of gas-
tric cancer patients, as compared to those from donors’ 
plasma [5] and highly metastatic sublines of rat prostate 
cancer cells [40]. Although we have no formal proof, 
similar characteristics (size, morphology, electrokinetic 
potential) of TMV isolated from GC1415 cell line may 
support our previous findings that at least some of MV 
found in blood of gastric cancer patients are of tumour 
origin [5]. Yet, their role in this type of cancer has to be 
established.
The present data from FACS, AFM and confocal 
microscopy provided unequivocal evidence that TMV 
attached to and were internalized by autologous tumour 
cells. Both FACS and confocal microscopy indicated that 
at 2 h of exposure the majority of TMV were seen extra-
cellularly, while at 24  h a large proportion of TMV was 
present inside the cells. Thus, between 2 and 24  h the 
entry of TMV occurred. TMV localized intracellularly 
were of different sizes, implicating their indiscriminate 
entry to the cells. This suggests that not only exosomes 
[9] may be taken up by cancer cells. There is an open 
question whether once engulfed TMV may be transfered 
to other cells. Furthermore, AFM analysis revealed that 
the exposure of cancer cells to TMV for 24  h, but not 
2  h, induced noticeable structural changes in the cells. 
TMV-untreated cells had smooth surface and sharp 
edge, as demonstrable by rapidly changing height at this 
point during examination. In contrast, the cells exposed 
to TMV showed blurred edge. This can be explained as 
caused by possible stronger adherence of TMV-treated 
cells to the slide and may be compatible with the possible 
alterations in cell movement. The question arises whether 
similar situation occurs at the tumour site where TMV 
are also present [1]. The cell surface showed crumb-like 
roughness and some protuberations, indirectly indicat-
ing intracellular localization of TMV. The present find-
ings are in keeping with the data on uptake of autologous 
exosomes by ovarian cancer cells [7]. Although, as judged 
by size, exosomes may be present among total TMV 
studied, they constitute only a part of all TMV. As PKH26 
labels all TMV, it may suggest the entry to the cells both 
larger and smaller particles.
Altogether, the above data suggest the important role 
of TMV in communication between cancer cells, which 
may lead to changes of their biological behaviour. In fact, 
in vitro exposure of GC1415 cells to TMV, for 24 h, but 
not 2 h, enhanced tumour growth and angiogenic activ-
ity of tumour cells in NOD SCID mice. This is consist-
ent with time of attachment to tumour cell surface (2 h) 
and engulfment of TMV (24 h), indicating that for these 
effects intracellular, rather than extracellular, localiza-
tion is important. It is of interest that enhancement of 
tumour cells induced angiogenesis was associated with 
an increased number of cancer cells in Matrigel plugs, 
This may imply the important role of TMV in support-
ing tumour growth. It is debatable whether enhancement 
of tumour growth is connected with transfer of HER-2/
neu mRNA and some TMV determinants, e.g. CD44H, 
CD44v6, CCR6, which are known to facilitate interaction 
of TMV with monocytes [8, 41]. There may be a special 
role for HER2 (EGFR) as molecule associated with CD24 
which together with phosphorylated Akt promotes breast 
cancer cell survival [42]. The exact mechanism of tumour 
growth enhancement by TMV may be multifactorial and 
requires further studies (on the way).
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Conclusions
TMV obtained from GC1415 cells showed significant het-
erogeneity in immunophenotype, size and morphology. 
TMV expressed some tumour markers and several mol-
ecules which may facilitate their attachment to parental 
cancer cells. Uptake of TMV, carrying these molecules 
and their mRNA, by GC1415 cells resulted in enhance-
ment of tumour growth and angiogenesis in NOD SCID 
mice. The presented data support hypothesis of auto-
crine tumour loops [43] in which TMV serve as macro-
messengers in delivering signals and molecular cargo to 
the neighbour tumour cells. Therefore, the engulfment of 
TMV by cancer cells may qualify them as potential natu-
ral carriers of anticancer agents.
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